Clinical Scorecard: Assessing the Efficacy and Safety of Romosozumab and Teriparatide in Osteoporotic Postmenopausal Women
At a Glance
Category
Detail
Condition
Postmenopausal osteoporosis with fragility fractures
Key Mechanisms
Romosozumab: anti-sclerostin antibody stimulating bone formation and inhibiting resorption; Teriparatide: PTH analog stimulating bone formation with coupled increased resorption
Target Population
Postmenopausal women with osteoporosis meeting specific BMD and fracture criteria
Care Setting
Outpatient endocrinology clinic in a hospital setting
Key Highlights
Romosozumab leads to significantly greater increases in bone mineral density at femoral neck, total hip, and lumbar spine after 12 months compared to teriparatide.
Romosozumab has a lower discontinuation rate and fewer cardiovascular adverse events than teriparatide in this population.
Romosozumab is contraindicated in patients with prior myocardial infarction or stroke and is avoided in high cardiovascular risk patients.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on BMD T-score thresholds (≤ −2.5 for ROMO; < −3 for TPTD) and recent fragility fractures.
Use dual-energy x-ray absorptiometry (DXA) to measure BMD at femoral neck, total hip, and lumbar spine.
Management
Romosozumab indicated for postmenopausal women with BMD T-score ≤ −2.5 and fragility fracture within 3 years.
Teriparatide indicated for patients with ≥2 vertebral fractures or 1 vertebral fracture plus BMD T-score < −3 within 3 years.
Avoid romosozumab in patients with prior myocardial infarction or stroke or high cardiovascular risk.
Teriparatide treatment duration limited to 24 months in Europe.
Monitoring & Follow-up
Monitor BMD changes at 12 months to assess treatment efficacy.
Monitor for adverse events, particularly cardiovascular events with romosozumab and osteosarcoma risk with teriparatide.
Risks
Romosozumab contraindicated in patients with prior myocardial infarction or stroke.
Teriparatide has a black box warning for osteosarcoma risk (dismissed in the US but not in Europe).
Patient & Prescribing Data
315 postmenopausal women with osteoporosis meeting reimbursement criteria in Denmark
Romosozumab showed larger BMD increases and higher treatment adherence compared to teriparatide; lower cardiovascular adverse events observed with romosozumab.
Clinical Best Practices
Select romosozumab for patients with recent fragility fractures and BMD T-score ≤ −2.5 without high cardiovascular risk.
Use teriparatide for patients with severe vertebral fractures and very low BMD (T-score < −3).
Perform thorough cardiovascular risk assessment before initiating romosozumab.
Limit teriparatide treatment duration to 24 months in Europe.
Monitor BMD by DXA at baseline and after 12 months to evaluate treatment response.
Consider prior osteoporosis treatments when interpreting BMD response.
